ArticleNature communications2024
A proteogenomic analysis of cervical cancer reveals therapeutic and biological insights.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Unlocking the potential of immune checkpoint inhibitors in advanced cervical cancer: a meta-analysis and systematic review.BMC cancer · 2025Pooled it
- Proteomic Biomarker Discovery in Breast Cancer: Advances, Challenges, and Translational Prospects.Journal of biochemical and molecular toxicology · 2026Review
- Molecular Insights from Differential Proteomic Profiling of Premalignant Cervical Lesions and Cervical Cancer.Pathogens (Basel, Switzerland) · 2026Article
- Article
- Cross-layer multiomic and digital pathology analysis identifies a malignant keratinization state linked to immune exclusion in cervical squamous carcinoma.Journal of translational medicine · 2026Article
- Acetylation in ovarian cancer: mechanistic insights into drug resistance and emerging therapeutic opportunities.Journal of ovarian research · 2026Review
- HPV genotype distribution and risk factors for cervical dysplasia among HPV-positive women with or without HIV infection in Shanghai, China.BMC infectious diseases · 2026Article
- Protein modification systems as cancer biomarkers and therapeutic targets.Precision clinical medicine · 2026Review
- CDNFE suggests FNDC3B and NECTIN4 as drivers of precancer progression via PI3K/AKT EMT.NPJ precision oncology · 2026Article
- Proteogenomics: decoding cancer in multiple dimensions.MedScience · 2026Review
- Proteogenomic characterization of cervical cancer identifies molecular subtypes predictive of clinical outcomes and subtype-specific targets.The Journal of clinical investigation · 2026Article
- Proteome-based molecular subtyping and therapeutic target prediction in cervical cancer.Biomarker research · 2026Article
- Role of human papillomavirus (HPV) variants and host genetic susceptibility in cervical carcinogenesis.Archives of microbiology · 2026Review
- Role of human papillomavirus (HPV) variants and host genetic susceptibility in cervical carcinogenesis.Archives of microbiology · 2026Review
- Prognostic impact of HLA-G expression in cervical squamous cell carcinoma: correlation with PD-L1 and CD8-positive tumor infiltrating lymphocytes.Frontiers in immunology · 2026Article
- Microbiome-Metabolome Crosstalk in HPV Pathogenesis: From Ecosystem Dynamics to Translational Biomarkers.Computational and structural biotechnology journal · 2026Review
- Research on the Mechanism of "Cold Tumor" Formation and Immunotherapy for Its Transformation into "Hot Tumor".Oncology research · 2026Review
- A machine learning-based framework for prognostic prediction and tumor microenvironment characterization of locally advanced cervical cancer with concurrent chemoradiotherapy.NPJ precision oncology · 2025Article
- Identification of Glutathione Synthetase as a Therapeutic Target for Cervical Cancer via Combining Bioinformatics and Experimental Validation.Journal of cellular and molecular medicine · 2025Article
- AUTO-SP: Automated Sample Preparation for Analyzing Proteins and Protein Modifications.Analytical chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
Abstract
Although the incidence of cervical cancer (CC) has been reduced in high-income countries due to human papillomavirus (HPV) vaccination and screening strategies, it remains a significant public health issue that poses a threat to women's health in low-income countries. Here, we perform a comprehensive proteogenomic profiling of CC tumors obtained from 139 Chinese women. Integrated proteogenomic analysis links genetic aberrations to downstream pathogenesis-related pathways and reveals the landscape of HPV-associated multi-omic changes. EP300 is found to enhance the acetylation of FOSL2-K222, consequently accelerating the malignant proliferation of CC cells. Proteomic stratification identifies three patient subgroups with distinct features in prognosis, genetic alterations, immune infiltration, and post-translational modification regulations. PRKCB is further identified as a potential radioresponse-related biomarker of CC patients. This study provides a valuable public resource for researchers and clinicians to delve into the molecular basis of CC, to identify potential treatments and to ultimately advance clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.